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TW" -PFFECTS OF SULFANILAMID"R 
Para-amino-benzene-sulfonamide (now officially 
sulfanilamide) (1) still crests the wave of popularity. 
Its level of therapeutic value may be ultimately found 
at the crest of that wave, for the drug has withstood 
severest criticism from the time of practical revela-
tion. Born in an ag9 in which medical science is 
dominated b~r therapeutic nihilists, promoted in the 
face of world cognizance of its attributes and sandy 
foundation, and existing while these pitfalls were 
illustrated and explained, no nemesis has yet been 
indicated. The only way in which sulfanilamide has 
completed its undulation-- fallen from its crest--
has only been apparent, for we are rising to a level 
at which therapeutic value has always remained, more or 
less the same, with those who have followed closely the 
rules set forth long ago for safe usage. These rules 
collectively only require intelligent supervision 
during administration, as will further be shown. 
Probably the main factor in keeping general im-
pression of therapeutic value from undulating was the 
affair with Massengill Company of Bristol, Tennessee. 
A drug known as "Elixir Sulfanilamide" was manufactured 
by this concern. The following proportion3 were used 
in this "elixir" (2): 
Sulfanilemide 
l\lixir flavor 
Raspberry extract 
Saccharin soluble 
Amaranth solution 1/16 
Caramel 
Diethylene glycol 
Water q.s. 
58t pounds 
1 gallon 
1 pint 
1 pound 
ll pints 
2 tlu1dounces 
60 gallons 
80 gallons 
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This solution was tested tor flavor, according to 
the Food and Drugs Act, but not tor effect on human 
lite. Consequently at least 73 persons died as a direct 
result ot taking this drug. Twenty others took the 
"elixir" but the exact cause of death could not be 
determined. 
~orld-wide publicity accompanied the confiscation 
ot this drug during the months or September and October 
in 1937. The company sent at least a thousand tele-
grams the first day, stubborn salesmen and physicians 
had to be dealt with by law, and a drag-net had to be 
set from coast to coast in a heightening drama that 
drew the scrutiny of all who would be interested. 
Congress required a report from the Secretary or 
Agriculture, and it was seen that the d1ethylene glycol 
caused the fatalities. 
Reverting from this parody in personal impression, 
the history of sulranilamide is seen to be brief (3) (4). 
In 1908 a chemist by the name of Gelino (5) was working 
on the azo dyes with an industrial interest. He first 
mentioned the paraaminosulfonamide compounds. There 
was no clinical application of the azo dye stuffs until 
years later when many compounds of these dyes with 
sulfonamide were made. ~isenberg (6) first conceived 
their bactericidal powers. From these investigations 
sprang scarlet red, included in "New and Non-official 
Remedies" by the .American Medical Association in 1912 
as a valuable drug in the treatment of chronic ulcers 
and wounds. At the Dusseldorf Dermatological Society 
on May 17, 1933, (2) it was reported bv Foerster that 
a red dye called Prontosil had had a remarkable effect 
in a child suffering from a staphylococcal pyaemia. 
Subsequently there were many reports on the effects 
of the dye chi~fly in hemolytic streptococcal infections. 
Domagk (7) however, was the first to offer experimental 
proof. He pointed out the antistreptococcic action of 
certain azo dyes in artificially infected animals. 
Soon after this some French investigators (8) showed 
that the active factor in this red dye Prontosil was 
para-amino-benzene-sulfonamide, later re-named sulfanil-
amide. Many other workers varified this work (9-11). 
The azo dye was seen to be not the essential component. 
It was proved that the p-aminobenzenesulfonamide 
group is set tree by the reduction of the prontosils 
in the body. In vitro also the prontoails must be 
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reduced before they become bacteriostatic. Mietzsch 
and Klarer ( 12) ( 1935) ma.de a new compound from the 
original prontosil by adding an azonaphthalene ring to 
the sulfonamide group. This compound was the red dye 
which has been known and used as prontosil soluble and 
as prontosil and now is to be called neoprontosil. 
Domagk's work with the original prontosil in mice gave 
the impetus to the tremendous strides now being made in 
chemotherapy. 
My purpose in writing this paper is to summarize 
the literature on this subject, attempting to procure, 
to my own satisfaction, a working plan for use of the 
drug, avoiding toxic manifestations. A recent case of 
toxic hepatitis in Omaha will be analized, and any-
thing that may be in common with the toxic manifes-
tations will be observed. The use of this drug in 
relation to the "practice of medicine" as well as 
to the "science of medicine" will be discussed from the 
influence of the reading. 
It must be here stated that, since well over 
two thousand articles have been published in the last 
three years and several good books written on the sub-
ject {13, 14), this paper, in its brevity, can not 
pretend to be unbiased in its conclusions. 
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The effects of sulfanilamide and allied compounds 
are well, though not completely, studied. It is in-
teresting to know that sulfanilamide was introduced as 
a specific chemotherapeutic agent for hemolytic strep-
tococcic infections. In such a capacity it promised 
to rival salvarsan in chemotherapeutic advancements, 
but it has broken from this specificity, for further 
experimental and clinical trials showed that it had a 
wide, but peculiarly selective, effectiveness. Certain 
organisms are influenced by it while closely related 
organisms, for reasons which at present cannot be 
appreciated, are entirely unaffected. 
Before the time when sulfanilamide was put to 
practical use clinically, there were many experiments 
carried on in attempts to understand the action of these 
compounds in vivo as in contrast to the action in 
vitro. Various organisms and many different experi-
mental animals have be.en used. Many conclusions have 
been put forth that warrant acknowledgement. These 
suggestions have been well summarized as follows (15): 
Sulfanilamide--
( 1) acts mainly as a bacteriostatic agent; 
(2) stimulates phagocytosis; 
(3) neutralizes bacterial toxins; 
(4) is bactericidal under certain conditions; 
(5) delays the growth of organisms until 
mononuclear phagocytes accumulate; 
(6) alters the organisms so that phagocytosis 
can take place. 
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The methods used have been quite variable and may 
account for many of the differences of opinion. The 
action may also be different with different organisms. 
The action of the drug as a bacteriostatic agent is most 
emphasized in the literature (11, 16-22). The very 
history of the drug implies that it has this effect, as 
has been briefly reviewed. 
The point in question in study of effects here is 
whether sultanilamide inhibits the growth of the 
bacteria, enhances the natural body defenses so that it 
can throw off the organism, or a combination of the 
two. The literature seems to show that the first of 
these is most obvious, but that the Dody defenses are 
bolstered as well, and now still further attributes 
are seen for the drug. There seems to really be three 
great groups of effects: (1) Those concerned with 
bacteriostasis, (2) those concerned with stimulating 
the natural body defenses, and (3) those concerned with 
destroying the harmful effects of the micro-organism, 
altering it in a way to spead the resolution of the 
infective process, or destroy it directly. 
In the early periods of sulfanilemide history, when 
the bacteriostaticaction of sulfanilamide was many 
times shown by inhibition of the growth of streptococci 
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in cultures, and Colebrook, ButtlA, and O'Meara (20) 
even exerted a belief thet there was a bactericidal 
effect in the presence of whole blood, it was immed-
iately though: that a similar effect in vivo might be 
the source of the therapeutic activity of the compounds. 
However, those workers who did find evidence of an 
inhibitory effect (23) felt that it was too slight 
to account for the remarkable qualities of the drug. 
Many d1.fferences in technique vary the results. 
Long and Bliss (13) state, "We were unable to test, 
satisfactorily, strains of hemolytic streptococci be-
longing to Group F, owing to the fact that with these 
minute organisms large inocula are required to start 
growth even in drug-free broth. vfuen su.fficiently 
large inocula were used no bacterioatasis was found. 
The same was true for the minute members of Group G, 
although the regular streptococci in this group were 
highly sensitive to sulfanilam.ide." Thus the size of 
the inoculum is very important. In the same way these 
men have shown that the age of the culture, the virulence 
of the culture, difference in the medium, dilution or 
the medium, s.nd other factors, make 1 t impossible to 
draw any definite conclusions, but the fact that some 
ben1f1 cie.l findings ere almost omni pre sent is an un-
impeachable fact. 
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Mellon, Gross, and Cooper (14) bring up the 
question of possibility of a shock effect of sulfanil-
amide. They bring up the point that there is always a 
possibility that the infection of a foreign substance 
intravenously may in certein patients bring about a 
reaction. No more material is apparent in this point 
since their writing. 
In connection with the idea thst sulfonamide 
compounds aid 1n phagocytosis Levaditi and Vaisman (23) 
advanced the theory that these compounds in some way 
interfere with the development of the capsules of grow-
ing streptococci and thus deprive them of their vir-
ulence. This would be of special interest in study of 
action on pneumococci. The many works of these authors 
(23) do not lead to any definite conclusions regarding 
relation to phagocytosis, and they are one of the most 
dominant teams working on the question. In May, 1935 
these men state that phagocytosis was only vigorous 
in the control mice of their experiments; Levaditi 
later claimed that an "1ntraleukocyt1c culture" was 
responsible for this confusion and stated that phago-
cytoais was enhanced; in June, 1935 they decided that 
it was more probable that the defenses of the germ 
were lessened; two years later their conclusions were 
still not definite. Other writers seem to offer the 
same indefinite results. 
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It is of note that the leukocyte pattern of the 
blood is not changed in any way by administration of 
sulfan1lam1de or allied compounds (24, 25). The blo0d 
elements found in the tissues are also unchanged (26). 
Moreover, the sulfonamide derivatives have been found 
by a number of observers to be harmless to various 
kinds of tissue cells in cultures when applied in the 
concentrations used therapeutically (23, 29). Further, 
it has been shown the,t no chemotropic effect upon 
polymorphonuclear leukocytes is exerted (28). 
The effect of sulfonamide compounds on the toxins 
of various micro-organisms or on the toxic affects of 
these infectious elements is a pressing question. This 
carries still deaper into detailed pathologic study. 
The effects of the compounds on various toxins have 
been studied by many men. Osgood and Brownlee (29) 
claim thet sulfanilamide neutralized the hemotoxin of 
streptococci after the manner of an antitoxin. 
By complicated study of the metabolism of micro-
organisms which have been subjected to therapeutic 
concentre.tion of sulfonamide compounds, it has been 
suggested by many works that, since this metabolism 
is in many instances altered, there may be a direct 
bactericidal affect in some conditions (30-33). 
10 
The most recent work to be published is that of 
Lockwood and Lynch (34). If this work is varified it 
will incite a differ~nt ettitude toward the mechanism 
of action of sulfanilamide than is now generally 
believed. These workers observed that amounts of 
peptone of only 1 mg~ in culture medium had a definite 
effect on the population curve, with or without sul-
fanile.mide, emphasizing the practical inaccuracy of 
most of the experimental work on the bactericidal 
action of blood and serum. Certain bacterial strains 
(apparently most of them) require these products of 
protein cetabolism to obtain nitrogen for their own 
metabolism. Thev seem unable to utilize the more 
complicated combinations. Thus, normal hurne.n serum, 
without sulfanilamide, 1 s not a good medi ·iJm for propa-
gation of even relatively invasive strains of hemolytic 
streptococci. On the other hand, the addition of 
peptone made the serum favorable for even the less 
virulent strains. The effect of sulfanilamide in vitro 
is, therefore, only maximal when even small traces of 
peptone are eecluded from the serum. Hence, it is 
likely that under these circumstances the serum medium 
is deficient in the readily assimilable nitrogen 
necessary for biologic activity. 
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Lockwood and Lynch worked on the hypothesis that 
sulfanilamide interfered with the ability of hemolytic 
streptococci to utilize protein-split products in serum 
and that the presence of peptone provided assimilable 
nitrogen in such excess that sulfanilamide could no 
longer act with optimal effectiveness. They state, 
"The precise mechanism by which peptone interferes 
with the action of sulfanilamide is, we believe, neces-
sary for any fundamental understanding of the action of 
sul.fanilamide in vivo." 
Working with freshly drawn human blood serum, 
defibrinated with glass beads, and an inoculum of young 
hemolytic streptococci, they prepared a series of tubes 
to incubate. In these were various concentrations of 
peptone and aulfanilamide together and separate. The 
same procedure was used with Bacillus coli in urine, 
and in a similar way the action of sulfanilamide on 
pneumococci and staphylococci, in human seriun, was 
studied. 
The population curves of the various concentra-
tions show that by decreasing the concentration of 
sulfanilamide or increasing the concentration of pep-
12 
tone the proliferation of the micro-organisms is en-
hanced by some direct or indirect fashion. The addi-
tion of peptone to sulfanilamide-free control serums 
produced a marked increase in the rapidity of outgrowth. 
A concentration of a hundred times as much sulfanllamide 
as peptone is necessary to produce bacteriostasis 
that is as great as in peptone-free serum containing 
sulfanilamide. 
In the same work, Lockwood and Lynch experimented 
with urine and soon saw that in the presence of peptone 
sulfanilamide no longer had the power to reduce the 
population curve of the colon bacillus. They point 
out the fact that in the course of tissue breakdown 
peptone is present in plentiful amounts, s.nd that this 
could account for the favorable action of sulfanilemide 
in the more generalized inf'ections as contrasted to its 
failure to get response in more localized morbidity, 
in most instances and reports. Ballenger and his 
associates (35) show that conditions in the urinary 
tract which might lead to an increased production of 
products of tissue breakdown may account tor failures 
of sulfanilamide therapy. Coincidently this seems 
highly feasible. 
The same relations between concentration of pep-
tone and sulfan1lam1de are shown with Staphylococcus 
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aureus are shown, and the effects of peptone on the 
actions of sulfanilamide and sulfapyridine on strepto-
cocci and the pneumococcus type III are studied. In 
the latter the action of sulfapyridine seems superior. 
It is of special note that the presence of from 
0.01 to o.l mg of peptone to a large extent overcomes 
the bacteriostatic effect of even 1 mg per cubic 
centimeter of sulfanilamide (See later-- local implanta-
tion). 
With reference to the possibility that sulfanila-
mide may act as an anti-catalase, these writers point 
out that it acts on Bacillus coli which is generally 
considered to be highly resistant to the lethal effects 
of hydrogen peroxide. 
Lockwood and Lynch offer amazing comment: 0 Normal 
human serum does contain minute auantities of free 
amino acids and other derivatives of protein catabolism. 
Since the organisms that are known to be susceptible 
to sulfanilamide are not in general actively proteo-
lytic, it is reasonable to suppose that when they are 
inoculated into blood serum they depend at least in 
part on obtaining assimilable nitrogen for protein 
metabolism from previously hydrolyzed protein. Since 
the concentration of such free amino nitrogen is rarely 
high it is obvious that the addition of very small 
traces of peptone may markedly alter the amount of 
assimilable nitrogen and thus significantly improve 
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the status of the serum as a culture medium for non-
proteolytic organisms, such as the hemolytic strepto-
coccus. The fact that effective sulfanilamide action 
depends on the exclusion of added peptone suggests 
immediately that the drug must act in some way through 
interference with the ability of the-bacteria to utilize 
the traces of assimilable nitrogen in whole blood, 
serum, urine or other body fluids. 
"It is possible that sulfanilamide combines in 
some way with the free amino nitrogen of protein 
degradation products and renders them unsuitable for 
bacterial utilization. This particular point is still 
under investigation, but other possible explanations 
of the precise mechanism involved are also being studied. 
Such a concept would appear to explain why the sulfanil-
amide compounds are active only age.inst certain or-
ganisms and in certain specialized mediums. 
"Furthermore, it would explain the failure of 
sulfanile.mide to destroy hemolytic streptococci in 
localized areas of tissue proteolysis, such as ab-
scesses or hAav1ly traumatized wounds. It would account 
for the failure of these drugs to act on the localized 
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suppurative lesions of staphylococcic origin and the 
successful results which have at times attended its 
use in diffuse staphylococcic cellulitis and bacteremie.. 
This hypothesis is consistent with the spectacular 
effects of sulfapyridine in pneumococcic infections, 
because of the minimel tissue injury in the lung in 
pneumococcic pneumonia." 
There will probably be much work similar to this, 
and its relations to the now prevailing concepts of the 
action of the sulfonamide compounds se~m obvious. This 
summary of the article will be later referred to. 
As previously shown, sulf~nilamide was first 
thought of as a specific for hemolytic streptococcic 
infections. This concept has waned. The following 
outline (36) summarizes well the morbid conditions 
upon which the drug has a satisfactory, therapeutic 
effect. This is here presented as a foundation for 
discussion "t;ecause it seems most representative of the 
literature. 
CASSS IN imICH SULFANILAMIDE IS CERTAINLY US'SFUL 
Acute hemolytic Streptococcus Infections. 
Streptococcus Meningitis. 
Primary Streptococcus Peritonitis. 
crrysipelas. 
Streptococcus Septicemia from any source. 
Puerperal Infections. 
Colon Bacillus Infections-- particularly of the Urinary 
Tract. 
Men1ngococcus Meningitis and Meningococcemia. 
Gonococcus Infections. 
Undulant Fever (Brucellosis). 
Chancroid (Ducrey•s Bacillus). 
CASES IN WHICH CLINICAL RESULTS ARE L~SS CERTAIN BUT 
IN WHICH THt<: DRUG MAY B"' OF VALUE 
Acute Streptococcus 
Tonsillitis 
Otitis 
Mastoiditis 
Sinusitis 
scarlet Fever 
Infections. 
Bronchopneumonia 
~mp ye ma 
Cellulitis 
Adenitis 
Cholecystitis 
Pneumococcus Infections. 
Urinary Infections with B. Proteus, R. Typhosus, 
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Staphvlococcus e.ureus, and possibly other organisms. 
Gas Bacillus Gangrene. 
Ludwig's Angina. 
Nonspecific Colitis. 
Malaria. 
Trachoma. 
CASES IN WHICH SULFANILAMID~ IS OF DOUBTFUL OR NO 
VALUE 
Most forms of Infectious Arthritis (lately successful). 
RheWD8.tic Fever. 
Staphylococcus General Infections (lately successful). 
Influenza Bacillus Meningitis. 
Friedlander Baclllus Infections. 
Putrid Lung Abscess. 
Urinary Infections With Streptococcus Fecalis. 
Subs.cute Bacterial ~ndocarditis. 
The earliest experiments, as shown in the intro-
duction, were with peritonitis in eeperimental animals. 
It is essential that chemotherapy be started early, 
before the peritoneum is much damaged. Meningococcus 
and gonocoecusinfections are remarkably held for re-
solution by sulfanilamide. 
In cases of streptococcie meningitis the use of 
1'7 
sulfanilamide has been found to bring amazing results. 
The disease was formerly thought to be practically 
always fatal. It was only a chance of one in a hun<lred 
that recovery would be reached. Gray (37) found only 
65 cases with recovery in the medical literature, and 
most hospitals have few records of recovery prior to 
use of sulfanilamide. In Johns Hopkins hospital (38) 
all patients admitted with this disease died, prior to 
institution of chemotherapy with sulfan1lem1de. 
Schwentker, et al (38), first reported the complete 
recovery of a patient suffering from such an infection 
in which the recovery was without a doubt due to admin-
istration of the drug. This marked the beginning of a 
new series of vital statistics as far as the disease 
was concerned. Arnold (39}, and Smith and Coon (40) 
also reported recoveries in the sam«~ year, and since that 
time there have been numerous reports of the success-
ful use of aulfanilamide in the treatment of h~molytic 
streptococcal meningitis (41-43). Neal (44) used a 
combination of neoprontosil and sulfanilamide. Long 
and Bliss (13} point out, however, that there is quite 
definite proof that Neoprontosil does not pass over 
into the spinal fluid, so there is little evidence which 
warrants the belief that the combined use of the drugs 
in hemolytic streptococcal meningitis is more effective 
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than is that of sulfanilamide alone. They state 
(page 169 in #13), "The available evidence tends to 
show that sulfanilamide has reduced the case fatality 
rate in hemolytic streptococcal meningitis from 97 per 
cent to about 35 per cent. This latter figure oan be 
made lower if the disease is recognized in its incep-
tion and then intensively treated with sulfe.nilam1de." 
It is surprising that the literature offers so 
few references to streptococcus peritonitis. Most are 
associated with puerperal infections. Colebrook and 
Kenny (24) reported a series of cases of puerperal 
sepsis treated with prontos11. or the ten patients, 
there were four with generalized peritonitis and six 
in which there were indications of a beginning gen-
eralized peritonitis. In this group of ten, there was 
one fatality. Foulis and Barr (45) reported four cases 
of generalized peritonitis with three recoveries. Long 
and Bliss (11) report one case with complete recovery. 
A recent article gives some good results with use of 
sulfanilamide in treatment of per1ton1t1s associated 
with appendicitis. It is to be noted, however, that 
this series is not of specific infection, (46). With 
reference to their series of peritonitis cases in 
general, they state, "The mortality in e. series of 
809 consecutive cases of acute appendicitis has been 
reduced from 1.5% in the first 552 cases to 0.4% in 
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the last 257 cases. This improvement is, we believe, 
the result of the employment of sulfanilamide in all 
severe cases in the latter group." In relation to 
feasability they state, "Sulfanile.mide readily diffuses 
into the peri ton,~al fluid in the experimental animal. 
All the available material indicates that the pori-
toneum is a favorabl3 site for the action of sulfenil-
amide." 
.... 
If means could be used to diagnose cases of primary 
streptococcus peritonitis, it is most probaule that the 
mortality and course of inf'ection could be reduced 
amazingly by employment of sulfanilam1de. 
There can t)e little doubt that the introduction 
of the sulfonamide compounds in chemotherapy has con-
siderably reduced the mortality of erysipelas. 
Toomey (47) reported 1907 cases. In the 1313 untreated 
cases the mortality was 15.5%, in those in which 
antitoxin was used (520) it was 13%, and in 74 cases 
in which sulfanile.mide was used the mortality was 4%. 
Snodgrass and his associates {48, 49) have shown that 
the mortality from th3 disease in the Ruchill Hospital 
in Glasgow, Scotland, has been reduced from 7.93 to 
2.3~. These workers all show that the clinical course 
of the disease is shortened as well es its danger to 
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life lessened. The disease has always claimed more 
pAople in the aged and young groups. These groups seem 
to be especially aided by the drug. If any abscess 
formation occurs, surgical drainage should be instituted 
to hasten recovery. Dosage for the infection is quite 
as is used in other cases, however, some feel that it 
is especially important to have a high blood-concen-
tration of the drug here. 
Most of the cases of septicemia, as with the 
peritonitis cases, are in relation to puerperal infec-
tion or local infection or such, where the diagnosis 
is inferred. Colebrook and his associates (20, 24) 
in 1936 reported 12 cases of hemolytic streptococcal 
bacteremia among their puerperal sepsis cases. Of 
these, eight were uncomplicated by coexisting per-
itonitis. These patients were treated with prontos11. 
In one of these cases the blood culture showed 5,oon 
colonies on the first two days of treatment, 3,ooo 
colonies on the third day, and on the fourth day of 
treatment the blood culture was sterile. The patient 
was discharged on the twenty-first day. In another 
case, aultanilamide therapy tor four days resulted 
in normal temperature and pulse, and in sterility of 
the blood which had previously yielded positive cultures. 
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In a third case the blood culture became sterile on 
the third day of treatment, metastatic abscesses asso-
ciated with the bacteremia rapidly resolved, and the 
patient's general condition raridly improved. In a 
rourth case, there was a spectacular remission of the 
signs and symptoms in twenty-rour hours after the 
beginning of treatment, followed by a steady improve-
ment of the patient's condition. There were three 
fatalities in this group of 12 patients. Foulis and 
Barr (45) encountered only one fatality in their series 
or cast:ts of puerperal sepsis among which eight, in-
cluding the fatality were septicemic. Robinson (50) 
presented a case of hemolytic bacteremia with broncho-
pneumonia following tons1llar enlergement and purulent 
cellulitis in the neck. Incision and drainage in the 
neck region was instituted and ant1soarlat1nal serum 
and sulfanllamide were used and the patient recovered. 
Seal (51) presented a case which followed a sinusitis 
and had concomittent joint involvement and recovered 
after administration of the drug. McCarthy {52) re-
ported a case of postscarlatinal hemolytic streptococcal 
septicemia which was cured e.fter use of neoprontos11 e.nd 
sulfan1lam1de. ~-.111tby (53) reports tour out ot five 
favorable results. In all these reports it seems to 
be essential that chemotherapy be maintained until 
complete recovery is obtained. 
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Other forms of septicemia. have been reported as 
responding fevorably to administration of the drug. 
Dyke ( 54) has reported that the ad.mini stre.tion of 
sulfapyridine brought about a prompt recovery in a 
patient who was 111 with a pneumococcal septicemia 
occurring a.fter a lobar pneumonia which wt::. s accom-
psnied b~1 empyema.. O 'Bri~n e.nd McCarthy ( 55) noted 
the recover;r of a patient who had been ill for sixteen 
days with a staphylococcal septicemia. Quite recently 
(56) two cases of bacteremia with Staphylococcus 
aureus hemolyticus were treeted b~.~ administration of 
sulfanila.mide with good results. 
Colebrook and his associates in 1936 (24) showed 
that there were such remarkable results from the use 
of the sulfonamide compounds in puerperal sepsis that 
the fatality of the infection could be astonishingly 
reduced. Their work is so clear that it leaves no 
room for doubt. The clinical reports of publications 
since ths.t time h8Ve not been able to enlsrge UJ-'On th'3 
point to any considerable extent. Further reports 
seem only to substantiate the more early work. Colebrook 
et al (5ry, 58), used the Prontosils in their treatment 
23 
and these drugs are still used in this disease. It 
was this early work which led to the more or less 
general use of the prontosils in cases where the in-
fectlng egent is a hemolytic streptococcus. There 
doesn't seem to be much indication the.t thev e.re ef-
fective in puerperal sepsis due to the anaerobic group 
of streptococci. Colebrook and Kenny (57) reported 
that from 1931 through 1935 the rnorte.li ty in p11erpere.l 
infections in Queen Cherlotte•s Hospital that werfl due 
to hemolytic streptococci varied from 16.6 to 31.ri 
per cent per year, while the number of deaths from 
streptococcal peritonitis varied from 15 to 23 per year 
during the same period. Prontosil therapy was started 
in January, 1936, and from then until August, 1936, 
64 patients 111 with hemolytic streptococcal puerperal 
sepsis were treated, with a case fatality rate of 
4.? per cent and one death from peritonitis. It was 
further noted in the treated patients that no pelvic 
masses developed arter treatment had been commenced. 
A prompt fall in the temperature within twenty-four 
to seventy-two hours was noted in the majority of the 
patients treated with the Prontosils. Rarely were 
recurrences of the fever encountered. Twelve of the 
64 pvtients had blood cultllres positive for beta 
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hemolytic streptococci when there_py was bEL1,un, 
and of these, nine made a prompt recovery. It was 
brought to Colebrook's attention that the case futality 
rate of the patients 111 with streptococcal puerperal 
f19ver ad.mi tted to the Northwestern Fever Hospi te_l in 
London had declined from 22 per cent in 1933 to 5.26 
per cent for the first half of 1936, while no such 
decline had been noted in the fatality rates recorded 
in puerperal sepsis in nueen Charlotte's Hospitel dur-
ing the same period. Thus there was the ouestion of a 
decline in virulence of the hemolytic streptococcus 
rather than the effects of Prontosil therapy which was 
causing the changed fatality rate. However, it was 
observed that, whereas the rates dropped at North-
western Fever Hospital, 'tt was only after the insti-
tution of Prontosil therapy that the death rate dropped 
at Q:ueen Charlotte's Hospital. Also it was concl1Jded 
that twenty or thirty of the more severe cases surely 
must have responned to th::i drug, for the recovery was 
phenomene.l. 
Coming to the urinary tract in the originally 
accepted outline for this therapeutic discussion it 
has this month, since the work of Lockwood and Lynch (34), 
become advisable to dissertate: Mellon and fellow 
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workers ( 32, 59) presented the ''Phenomenon of Poten-
tiation". In explaining this phenomenon they cerrted 
out lF~ngthy experiments. 'l1hese men had a cc..se of 
meningitis which recovered with grBet rapidity after 
the administration of sulfanilamide. They used the 
bacteria from this cese for in vitro experiments since 
they assumed sulfanilamide should undoubtedly have 
remarkable effect on this strain. They made their 
dilutions using a broth as a diluting D"enstru··im, and 
found that the bacteriostatic effect of the aulfanila-
mide was completely lost in 24 hours, and wa.s not s.s 
appreciable, as it surely was in their patient. They 
then pro ceded to use various dil1;tions of serum and 
combinations of serum end broth, and found the bacter-
iostatic action of the sulfanilamide still not sufi'i-
cient to account for thA remarkable effect in vivo. 
Next they made their dilutions in an 0.85 per cent 
solution of sodium. chloride and founn that th~ number 
of colonies was less with and without the sulfanils.mide. 
They here pointed out that this solution of sodium 
chloride itself had a bacter1ostat1c effect. The 
bacterioststic efi'ect was then studied when serum and 
salt were used in verious dilutions, and then they 
carried out the dilutions with ser1Jm, salt and sul-
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fanilamide. Here they found that instead of a summat-
ing bacterioste.tic effect of the salt and the sulfe.nil-
amide an even far greater static effect was noted. 
Therefore, they concluded thnt there was a "potentiat-
ing" effect of the salt so that the effect of the sul-
fanilamide approe.ehed thB.t cssumed to have taken rlace 
in the body of the pstient with the remarkable re-
covary. 
Besides showing the probability of many mistakes 
being made in such wor•k, they also brought up me.ny 
new questions relative to the effects of aulfanilamide. 
Many of these were directed to therapy in urinary tract 
inf'ections. "Does the urine potentiate sulfanilamide's 
action in infections of the genito-urinary tract?" 
they ask. They poin'::.. out that in cases of cystitis, 
pyelitis, and such it seems most possible that the in 
vitro bacteriostatic effect of the sodium chloride 
could be transferred. 
Kenny, et al (60) have shown remarkably rapid 
sterilization of the urine in 4o cases of pyelitis due 
to Bacillus coli after administration of' sulfan1lem1de. 
The urine often contained as many es 125 m11L1.on 
organisms per cubic centimeter in advance of tre~tment. 
In attempting to find the ans1ver to their quer,:'y 
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concerning urinary tract infections Mellon, et al 
prepared a series of dilutions, seeded with a micro-
organism obtained from a cystitis ce.se. Th'3 dilutions 
were mcde, respectively, in broth alone, urine and 
broth and urine alone, 80 that all possibilities of 
combinations of' culture medium, diluent, test medium 
and concentrations of sulfanilamide were used. From 
this work they had wonderful evidence to conclude that 
"a critical be.cterioste.tic ef'fect of sulfan1lamide can 
only be obtained in vitro under conditions where the 
organisms are not only tested in urine, but diluted in 
urine e.s well. If they are diluted in broth, even though 
the tests are made 1n urine, the effect of the sul-
f'an1lamide is negligible." 
Thus it was shown that thP. sulfanilamide worked so 
marvelously in urine because urine was the only medium 
present. The urine, they theorized, had the "poten-
tiating effect" that they had previously attributed 
to a solution of normal saline. They also pointed out 
that when there was any tissue destruction present in 
cases of pyelitis or cystitis the sulfanilBmide no 
longer was a8 effective. This, they argued, was due to 
the changes in the chemical make-up of the urine in 
the presence of the protein cstabolism, end was quite 
similar to their in vitro experiments where they 
diluted their seeded urine with broth or used the 
broth as a test medium. 
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Now this work must be correlated with the recent 
work of Lockwood and Lynch (34), previously described. 
It will be remP-mbered that they concluded thet sulfan11-
am1de acted only in the presence of a limited amount 
of peptone, and thus they explained the fact that the 
drug could combat an acute, generalized infection, 
whereas, it could not cope with a situation in which 
there was tissue destruction, because of the presence 
of an overwhelming amount of peptone from protein 
catabolism. 
In projecting Lockwood and Lynch's work on that of 
Mellon, et al, ~e can see that the reason sulfanilamide 
acts in the urine dilutions and not in the broth dilu-
tions, in the saline dilutions and not in the broth 
or broth-serum dilutions, is that there is plenty 
available nitrogen in the form of break-down products 
of protein in the broth, which are obviously not pre-
sent in the sBlt, or appreciably so in the urine. 
However, es pointed out, the drug did not work in the 
face of tissue destruction. Here again it could be 
that this is because of the presence of peptones. 
This seems a logical explaination of a great work. 
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The urinary tract infections, as above described, 
are much nee.rer in vitro experiments than anything 
worked with heretofor. Once more 1t seems that the 
urologists have the oportunity to do thourough work, 
with a profound understanding, beceuse they can see 
whHt they are doing. On the other hand, if this work 
holds up, the action of sulfanilam1de throughout the 
body can now be better visualized. 
1.\Torking in this body system, and with these 
theories, another major point is brought to view. That 
point is the complete lack of specificity of the 
sulfonamide compounds. It is now more than ever seen 
that it is not the genus or species of the micro-
organism that is concerned so much as the manner in 
which it manifests itself in its morbid activity in 
the body. Many micro-organisms seem to have no sus-
cepta.bili ty to the therspeutic action of sulfanilEimide 
whatsoever, but the most of them have shown some week-
ness. In the body, however, many of these infectious 
agents manifest themselves in such a manner that it is 
improbable that they will ever be satisfactorily com-
bated bv these known methods of chemotherapy. 
In a recent article (36) some cases of urinary 
tract infections were analyzed according to the or-
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ga.nisms in the following cha.rt: 
URINARY rpRACT INF';'CTIONS ACCOHDING TO 
Cases 
ORGANISMS 
Cured 
B. Coli 
B. Proteus 
B. Friedlander 
B. Pyocyaneus 
Staphylococcus aureus 
Nonhemolytic Streptococcus 
H:nterococcus combined with B. Coli 
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12 
2 
2 
2 
2 
3 
22 
2 
0 
1 
1 
2 
1 
N"" 
A great many different micro-organisms have been 
e'~perimented w1.th and tried in clinical combat. It 
is sufficient to say here that most have some response 
reported, so the drug may be tried, at least. 
It is important to beware of kidney damage in 
administration of sulfanilam.ide. After several days of 
chemotherapy there will be a considerable hBaping up 
of blood concentration of sulfanilamide if it is not 
properly excreted. Another important thing to remt=imber 
in dealing with the urinary tract is that a.bout half 
or the drug is in the urine in its inactive conjugate 
form. This is the acetyl derivative that is also 
found in the blood stream. There is a considerably 
greater amount of this form found with the administra-
tion of sulfa.pyridine, but this drug is superior in 
action in many instances. Because of the greater 
amount or the conjugate form, crystals often bring 
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havoc es will ltiter be shown in the discussion of 111 
e.ffects. 
Schwentker, Gelman, s.nd Long (61) withheld specific 
mAningococcal antiserum in ten cases of meningococeal 
men1ngi tis 1n 193'7. Instead, they administered sul-
fanilamide subcutaneously and 1ntrasp1nally, and all 
but one o.f these patients recovered. The one .fatelity 
was very ill on adnission and was considered lost any-
way. There were signs o.f encephalitic involvement in 
this case, and concomittent pneumonia was met on the 
.fi.fth day. The spinal fluid of this patient had been 
sterile for three days and there was a mBrked reduction 
in the spinal fluid cell count to 158 cells on the day 
of death as a result of sul.fanilamide therapy. All 
petients responded with a reduction in the spinal 
fluid cell count which occurred progressively beginning 
with the institution of the therapy in some eases and 
precipitously, e.fter several days, in others. The 
spinal fhlid and the blood during this time !Jece.me 
sterile. In addition, a child that had meningococcal 
sept! cemis. without meningitis, ''as also cured in thA 
same mannar. 
Harvey and Janeway (62} mentioned the case of e. 
ten-month-old baby manifesting meningococcal meningitis 
that was recovering as a result of sulfanilernide therepy, 
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but developed hAmolytic anemia which necessitated a 
number of blood transfusions. The petient recovered. 
Among the more extensive confirmatory papers ere those 
of Banks ( 63) and ,,,e.ghe lste in ( 64 ) • rrh~ se and many 
more reports show this to be one of the astounding uses 
of the sulfonamide compounds. There are me.ny points 
to consider in therapy here, the details of which 
cannot be dis~1ssed. There ere differences in which 
the sulfonamide compounds diffuse into the spinal 
fluid. The f·rontosils seem to diffuse most poorly. 
There is a lag in the concentration in the spinal fluid 
as contrasted to the blood concentration. The use of 
intraspinal administration has been less prominent 
in late reports, but it may have its place. Combina-
tions with antiserum ~re used also. 
Long and Bliss (13, page 188) report excellent 
curative results after intensive there.py with the drug 
in five patients suffering from acute meningococcemia, 
without signs of meningitis. 
One of the most important developments in the 
administration of sulfanile.mide was the introduction of 
treatment of gonorrhea by this method. The first 
significant reports with favorabl~ results were by 
De9s and Colston {65) and Herrold(66). Since that 
time a great deal of literature is to be found. Among 
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the few who found unsatisfactory response are Anwyl-
Davles (67), and Brunet, Reinhardt an~1 Shaw (68). 
There is no unanimity of opinion ns yet, regarding the 
optimum time for beginning treatment, the amounts of 
th~ drug that should be used, the duration of therapy, 
or the auxiliary measures which should oe instituted 
in the course of treatment. It seems, from a review 
of the various opinions upon the subjBct, that the 
later therapy is started in the course of the disease 
the more successful are the ultimate results. In 
Dees and Colston's original paper (65), it was noted 
that while failures in treatment occurred in only 7.5 per 
cent of fresh cases, 11.5 per cent of the patients 
previously treated by other methods did not respond to 
sulfani lamide. Herrold, however, reported the.t only 
four of 14 patients 111 with acute gonorrhea made a 
quick response to sulfanilamide therapy. He also 
advanced the possibility that better results would be 
obtained in new infections if the petlent had previously 
had gonorrhea than in those individuals suffering from 
their first attack. 
Many of the early reports on the use of the sul-
fonamide compounds were dissappointing because the 
wrong drug was used. Prontosil therapy is now known 
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to be unsatisfactory. .4.s before brought out in this 
paper, in view of the present knowlHdge of drug action, 
the effects in the urinary tract ar9 quite similar to 
the in vitro reactions, and the prontosils must be 
reduced to an active form in vivo before they will 
have a bacteriostatic effect. There is no reducing 
agent in the urin~ of sufficient power to do the work 
of the magnesium powder in vitro. 
ll\fi th reference to the previously made ste tement 
that it seems that therapy is best started after the 
disease has been active for a few days or more, Alyea 
and his co-workers (69) concluded from their studies 
that the patient who starts treatment a week after the 
onset of his discharge has an equal chance of being 
cured with one who :Jegins treatment ~arlier. Breakey 
and Harrold (?O) however, reported that the average 
duration of infection was twenty-one days in their 
acutely 111 patients, and fory-five in the chronic cases 
when treated with sulfanilemide. This is to be con-
trasted with an average duration of infection of one 
hundred and four days in 50 of their patients treated 
previous to the introduction of sulfanilamide. Colston 
and his associates (71) divided their patients into 
those who had anterior urethritis, anterior and post-
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erior urethritis, and anterior and posterior urethritis 
with complications. The average duration of the disease 
in these three groups was twenty-seven, twenty-eight, 
and thirty-three days respectively. 
In the last year there have been reports, too 
voluminous to describe in this paper, of the use of 
other sulfonamide compounds in the treatment of gon-
orrhea. Many men are now using sulfapyridine for chem-
otherapy here. Since this drug acts in a fashion 
similar to sulfanilamide, and in many instances show 
greater action, it is probable that the success claimed 
for it is well founded. It must be rf:~membered that 
well over half of this drug is in the acetyl derivative. 
This product is inactive and is to produca harmful 
crystal deposits in the urinary tract. Consequently, 
the drug must be used '·'i th care, and the fluid balance 
of the patient es well as his acid base balance must 
be well watched. Theso, dangers will be discussed later. 
Roth (72) reported a series of cases of specific 
urethritis, for which he used Disulon, a brand ~f 
sulfan1lyl-sulfanilam1de, for chemotherapy. In a 
group of 44 cases of acute gonorrhea treated with 
sulfan1lam.1de he obtained a 47% fraction of complete 
cures in two weeks. In a series of 22 cases that were 
treated with sulfanilyl-sulfanilamide he o'otained 
73% cures in this same length of tiMe. In a series 
of his private cases, at the same time, he reported 
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?1% of 42 cases resulted in two-week cures when treated 
with potassium permanganate irrigations and sulfan11-
amide. 1:V1th the same irrigations but 1.'ITith Disulon as a 
chemotherapeutic agent he obtained 92% cures in two 
weeks. There were also 12 cases which did not respond 
to sulfanilamide that did respond to Disulon. 
In the face of such reports as this for other 
derivatives, it surely is advisable to try sulfapyridine 
or sulfanil:yl-sulfanilamide if good results cannot be 
outained with sulfanilamide. 
That sulfanilamide is extremely beneficial ther-
apeutically in oases of uncomplicated gonorrhea has 
been shown by many workers (65,66,73-76) however, 
there are still other attributes offered for the drug 
in infections where the gonococcus is the infectious 
agent. Coggeshall (7?} et al report a series of cases 
of arthritis from the gonococcus. They showed that in 
' 
cases of gonorrheal arthritis the sedimentation rates 
fell very rapidly upon administration of the drug, 
showing striking and immediate relief. The sedimen-
tation rates remained the same for a similar series or 
cases suffering from rheumatoid arthritis where no 
change of the clinical course was observed. They 
showed how the largest percentage o:f clinical cur>es 
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can be obtained in pe.tients 'd th gonorrh9al arthritis if 
sulfanilamide in doses sufficient to maintain a blood-
aulfanilamide level of 10 mguf' or higher is maintained 
for a week or longer, and it is administered early. 
There is a recent report (46) of a series of 100 
patients with gonorrhea who were treated with sulfanil-
amide alone resulting in 45% cures in two weeks. The 
writers suggested that giving vitamin C with the drug 
would improve the figures. They also used it with 
gonococcic vaccine and obtained 81%' two-week cures. 
'*'ithout a doubt, the use of aul:fan11amide in treat-
ment of gonorrhea will do a great deal in helping to 
rid the populace of disease, and to relieve them in 
suffering. 
Brucella infections have attracted much interest 
of workers with sulfanilamide. There is a good deal 
of work done "1th these micro-organisms to try and 
determine whether or not the drug has any effect on 
antibody formation. Welch, Wentworth and Vaisman (78) 
did much work on this subject and finally concluded, 
"In Brucelle. infections sul:fe.nilam.ide appears to act 
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through stimulation of the defense mechanism of infected 
animals by increasing the production of specific 
opsonins, thus effecting neutralization of the endo-
toxin or aggressin-like substances, with resulting 
phagocytosis. 11 
Kato and Lane (ry9) reported the case of a six-
year•old girl suffering from undulant fever who was 
treated with sulfan1lamide. Two relapses occurred, 
each of which was also similarly treated. No conclusions 
were drawn nor was any statement made of the effect 
of the drug on the clinical course of the disease. 
Heretofore, chancroid has been a stubborn afflic-
tion to handle. Therefore, the medical field is pleased 
with the marvelous results obtained with sulfanilamide 
therapy. Many workers have reported good response 
(80-84). 
Hutchison (81) has observed that formerly it 
required an average hospital attendance of forty-six 
days before a che.ncroid with or without bubo was 
cured, and incision of the bubo had to be performed 
in five out of six cases. Since the introduction of 
sulfanilemide therapy in this disease he had not 
performed an incision and the average hospital at-
tendance had been reduced to fifteen days. 
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A great deal of the illness found among patients 
in a general practice is due to tonsillitis, pharyn-
gitis, and sinusitis. Since the introduction of 
sulfanilamide it has carried the reputation of being a 
more or less specific drug for streptococci. Con-
sequently in many cases of pharyngitis it has been 
immediately administered because of the impression 
that most of such infections are due to the strepto-
coccus. Even when this is the infectious agent, it 
must again be emph~sized that the material on the 
effects of the drug, more arrl more show that it is not 
the infecting micro-organism that is entirely respon-
sible for whether response will be had or not. The 
way in which that infecting agent manifests itself in 
the morbid condition must also be considered. 
In agreement with many men recently before them, 
Rhoads and Afremow (85) report e series of sore throats 
from which hemolytic streptococci were cultured. Half 
were treated with sulfanilamide and half were not. 
Some cases had to be dropped from the series because of 
toxic reactions whicll necessitated the discontinuance 
of the drug after a few days usage. They found the 
drug not to reduce the severity of the symptoms, 
shorten the period or incapacity or reduce the incidence 
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of complications. The carrier state was also sePn not 
to be shortened because the cultures were positive for 
a longer time in the treated group. The treeted group, 
probably coincidentally, wes hospitalized longer than 
the control group. Careful study of the reports 
presents the impression that if th·~ two columns were 
not labeled on? could no~ tell one from the other. The 
only differences in the courses of the two columns is 
that toxic manifestations of the drug other then the 
usual cyanosis occurred in one half of the cases in 
which sulfanilamide was administered. In some instan-
ce a these reactions even brought serious concern. 
These writers conclude, 11 It is not wise to make sweep-
ing generalize tions on the base of one serie a of 
controlled ca.sea. Sulfanila.roide is a drug of proved 
value in severe infections of deep structures due to 
the hemolytic streptococcus. Rowever, in the average 
uncomplicated case of tons:tllitis orpharyngitis due to 
hemolytic streptococci the advisability of its routine 
use is questionable. Certainly no physician shnuld 
be censured for withholding the drug in these condi-
tions unless complications such as severe cervical 
adenitis, para.nasal sinusitis, ot1-tis media., mastoid-
itis or meningitis supervene. 11 
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Long e.nd Bliss noted that sulfanilan;ide therapy 
radically altered the course of a~1te streptococcal 
otitis media (30). Since that time many other ob-
servers (86,42} have varified their reports. Hageman 
and BlakA (86) reported that all of 11 patients suf-
fering from otitis media recovered from their d:isease, 
without complications, following sulfanilamide therapy. 
The problem of whether it is a wise procedure to 
treat a simple acute streptococcal mastoiditis with 
sulfanilamide alone is a difficult one. Hageman and 
Blake (86) have reported that only two of 11 patients 
who were treated with sulfe.nilamide for acute strept-
ococcal masto1dit1s required mastoidectorny after sulf-
anilamide was started. In nine instances the disease 
subsided without surgical intervention. ThAse men also 
recommended the use of sulfanilemlde in treatment of 
acute mastoiditis following mastoidectomy. These men 
reported, as well, that only one of nine cases of pur-
ulent hemolytic streptococcal sinusitis required sur-
gical treatment after sulfanilronide had been started, 
and in this one patient a mixed becter:lal infection was 
present. Other observers (8'7,88) have stated that 
they noted favorable effects following the therapeutic 
use ofthe drug in acute sinusitis. These men also 
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noted remarkable response of chronic otitis media and 
mastoiditis. 
Long and Bliss (13) state that they heve had ex-
cellent results in trea.tment of cellul1 tis with sulf-
anilamide. They show that the use of wet soaks or 
packs, es is customary, 1s unnecessary as an adjunct 
to the treatment, anoit may do harm because it leads 
to abscess formation. They state that the drug should 
be continued until at least two days of normal temp-
erature have elapsed and there is a merked regression 
of the local lesion. Thereafter it should be continued 
in lessened doses until recover'T is complete. If an 
abscess is incised, the drug should be continued in 
small amounts until the wound has healed. 
Hageman and Plake (86), and Mcintosh and Wilcox 
( 87) have shown fine results from sulfanilamide therapy 
for lymphad.enitis from hemolytic streptococcic infection. 
They give lower blood concentrations of the drug than 
is usually held for other infections. It may be 
promptly discontinued when the lymphadenopathy hes 
receded. Here again the soaks seem unnecessary. 
Hageman and Blake (86) and Fleming (89) first 
have shown good results in chemotherspy for hemolytic 
streptococcal pleurisy. Surgical intervention should 
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be used only if absolutely necessary, they insist. 
There is a ~od deal of conflict of opinion re-
garding the effectiveness of sulfanilamide against 
scarlet fever. Paul N. Morrow of the University of 
Nebraska College of Medicine tells of a very large 
series he followed on pediatrics et The Philadelphia 
Hospital for Contagious Diseases. The final obser-
vations were so contusing that the variations could 
all be from imperfect stetistical methods. There was 
no tangible improvement under this therapy, either in 
course of disease or number of complications. 
Mellon (14) discusses scarlet fever at great 
length in setting forth criteria or therapeutic effici-
ency, with reference to sulfanilamide. He reminds the 
reader of the mistaken impression that once prevailed 
concerning the similarity of streptococci. Workers 
then thought that if a serum should be effective against 
erysipelas it should also be effective against scarlet 
fever. However, it was soon found that the serum used 
for one not only would not work on the other, but the 
serum for the erysipelas of adults would not combat 
that of the infant, 1n which the mortality from the 
diseese ranges from 80 to 90 per centl He (14) de-
scribes sulfanilamide as a "non-specific serum", going 
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on to discuss the variation in age of the patients 
suffering with erysipel~s who respond to therapy. Here 
again the error is seen in thinking that sulfanil-
e.mice is a specific chemotherapeutic agent for strep-
tococcic infections. Once more it must be stressed 
that the ability of the drug to act seems to depend 
not only on the micro-organism concerned with, but 
also on the manner in which the.t micro-organism mani-
fests itself in the morbid process in the body. 
Observing this fine variation in strains of 
streptococci it is no wonder that reports vary so 
much on effect of the drug on scarlet .fever. The 
writings are so voluminous on this sulJject that they 
cannot be completely covered h~re. It may be stated, 
however, that .for every attribute found for sulfanil-
amide in this instance there is a contrary one. Sako 
and his associetes (90) conclude, a.fter study of an 
extensive series, that thA drug should be used &.t the 
onset of the disease, and, although it does not alter 
the course of the fever period, it considerably cuts 
down on the number of complications. On the other 
hand, Toomey (91) concludes, after a similar study, 
that the drug does not cut down on the number of 
complications at all, but should be used if these 
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complications arise. Now, when we can realize that the 
drug has no action against most infections where there 
is a local problem at hand, we wonder if it cen ue 
of any benefit for these complications, since they are 
of such a nature in most instances. Surely, the tissue 
destruction in a pharyngeal abscess would prevent any 
local action of sulfanilarnide, and it has been prev-
iously shown that only part of the cases of otitis 
media are of a nature that will slow action of the 
drug. Still, at the same time it was shown that, in 
view of occasional benefits, it should be tried in 
most cases. 
In cases of scarlet fever, surely, if signs of 
toxic reaction are met, the drug should no longer be 
administered, for there is no indication that sulfanil-
amide is a very important therapeutic agent. 
The introduction of sulf apyridine has brought 
many favorable reports concerning its use in combating 
pneumococcus pneumonia. Prior to this development the 
benefits derived from the sulfonamide compounds in 
treatment of lobar pneumonia were scant and in no way 
comparable to the results achieved with antiserum. 
Heintzelman, et al (92), offered one of the earliest 
works in this line. Nineteen cases of pn~umococcus 
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pneumonia were reported by them.. Nine were treated and 
ten were used as controls. The pneumonia was of Type III. 
Seven of the nine treated cases recovered, and two 
dies, in contrast to the ten untreated cases, among 
which two patients recovered and eight died. They 
found that if the drug was given early in the disease 
the chances of benefit fr~m it was better. A few other 
workers (93,94) also gave favorable reports of the use 
of sulfanilamide in the tr~atment of lobar pneumonia. 
However, there seemed to be no evidence that broncho-
pneumonia would respond. Evans and Gaisford (95) 
were the first men to report the fine response of 
pneum.ococcus pneumonia to sulfapyridine. A hundred 
ps. tient a who were suffering with the di see.se were 
treated with the drug and a hu11dred others were given 
only symptomatic treatment. There wes no apparent 
difference in ages of the two groups or in variance of 
the types of pneumococci discovered. The cases were 
all received at the ss.me season of the year and from 
the same loca.li ty. Only 44 of the 200 patients were 
successt"uly typed. The fatality rate in the treated 
series was eight per cent, whereas in the other group 
the rate was 2? per cent. Of those patients who re-
covered, 44 had a normal temperature by the sixth 
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day in the treated group, while only 20 in thA untreated 
series had normal temperatures on. the sixth day. If 
the treatment was discontinued too soon in the course 
of the disease, secondary fevers assoc:i.ated with 
recurrences or a spread of the pneumonia were noted. 
Following this impressive report, there was much 
study of chemotherapy for this disease (96-100). These 
papers were not only conrirmBtory in nature, but they 
also l):)came increasingly more demonstrative of success, 
until now it is frequently a decision to be made-- to 
use the drug or the serum. The journals of the year 
1939 carry too much material to describe in the space 
here alotted. Suffice to say that results are about 
as good in cases treated with sulfapyridine as in cases 
treated with antiserum (101). Most writers emphasize 
the fact that patients should still be typAd because of 
occasionally finding one who does not respond satis-
factorily to drug administration. Some recommend use 
of both the antiserum and the sulfapyridine. This use 
of sulfapyr1d1ne is far superior to similBr use of other 
sulfonamide compounds that have es yet been tried. 
(101,102) 
As this paper is today written work is being done 
with sulfapyridine in treatment of pneumonia. The 
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Omaha World Herald (Tuesday, March 19, 1940) carries 
the following Associated Press dispatch: "New York 
' 
March 18-- A displav showing a drop of 40 thousand in 
pneumonia deaths in the United States in the la.st yesr 
will be one of the new exhibits at the New York world's 
fair this summer. 
"Sulfapyridine, the new medicine for pneumonia, 
will be shown as playing an important pert in this great 
saving. l~ether the surprising drop from 130 thousand 
deaths in 1938 to 91 thousand in 1939, was all due to 
the new remedy is not yet known. 
"Medical reports he_ve p'ointed to the possibility 
some or the decrease in 1939 might have been because of 
milder types of pneumonia that year. 
"However, the exhibit will contain evidence thet 
aulfapyridine lest year cured nine out of every 10 
persons to whom it was administered." 
It is interesting to note that in the s~me edition 
there is evidence, through the International News 
Service, that two persons, one in Chicago and one in 
San Francisco, were showing wonderful response to 
sulfanilamide administration for ataphylococcic sep-
ticemia. The pace these drugs are setting is phenom-
enall 
49 
One of the most talked of uses of sulfan1lam1de 
the last few months is its local i~plantation. The 
amount of talk, end probably the amount of use of this 
nature seems to far surpe ss the 11 tere.ture on the subject. 
An obstetrical term ago Jensen, Johnsrud and Nelson (103) 
reported local implantation of the drug in compound 
fractures with favorable results. These men treated 
39 compound fractures with this local 1r:iplentat1on of 
thA drug and as a result found no single primary wound 
infection. Of 94 cases treated in as nearly exact 
fashion as possible except for the local implanta-
tion, 27 per cent resulted in primary wound infection. 
These men pointed out the following factors to be 
concerned with here: Sulfanilamide crystals in a wound 
dissolve slowly. The lest of the drug leaves the body 
in about 60 hours. Marshall, At al (104), showed that 
after one single large dose of sulfanilamide, the lEst 
of it was excreted by 24 hours. Therefore, Jensen, 
et al concluded that th~re must be still some of the 
sulfa.nilsmide at the wound site for at lee.st 18 hours. 
Th'3se latter men go on to state that the highest 
blood level of the drug in their patients so treated 
was found in 18 hours. These latter men go on to show 
that since the solubility of sulfanilamide is 0.8 
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per cent at body temperaturA, thts concentration of 
the drug is prnbeble e.t the wound site. 'fhus a C')n-
centration of 800 mg%' is :ms.intained for a considerable 
length of time, wherees only 10 to 2n mg% can safely 
be maintained by administrstion per os. From these 
facts it csn be seen that a concentration of 80 times 
the me.gnitude is theoretically obtained. '.rhese men 
conclude that th:ls manner of treatment uses a bacter-
icidal effect of' th'.3 sultanilamide for organisms more 
susceptible t 1J the drug and a bacteriostatic effect 
for others. 
Jensen, et al did some experimenting with guinea 
pigs in the following manner. The7 used seventeen 
animals. Seven were used as controls. In the controls 
they fractured a rib with scissors through a wide 
incision, end in the other ten 0.5 gm of sulfanilamide 
was implanted in similarly produced compound fractures. 
Five out of the sevan controls had primary wound in-
fection, while seven out of the 10 of the others healed 
uneventfully. Of the ten treated animals it is of 
note thbt one of the three which suffered infection 
was not closed tightly, to observe the effects if th~ 
drug could fall from the wound, and another of those 
infected had had blood dravm f'rom 1 ts heart at frequent 
intervals. 
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Jensen, et a.l conclude from their fine study 
that, "The local use of sulfe.niledde has open1d the 
way for more effective treatment of contaminated 
wounds. The amount to be used in each specific wound 
depends upon the extent of trauma and contamination." 
They recommend 5-20 gm (no more), and show the neces-
sity of painstaking de bride men t • rrhey i)e lieve the 
drug only bacteriostetic against staphylococci, even 
in concentrations approaching one per cent. 
Since the work of Lockwood and Lynch (34) with 
peptone broth it will be interesting to see further 
work in this line. Lockwood and Lynch show that a 
concentration of sulfanilamide must be a.bout 100 times 
that of the products of protein catabolism before there 
is therapeutic effectiveness. Work is therefore 
warranted in these higher concentrations. The con-
centration of pei t;;ne in the tissue :fluids at a wound 
site CD uld easily be 10 mg~~' and if this concentration 
were reached the concentration of 800 mg% of sulfanil-
amide would be insufficient. 
This would encourage complete debridement as 
recommended by Jensen, et al (103). On the other hand, 
it seems there has been evidence (before presented) 
that certain instances '.'There there is a small degree 
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of tissue damage as in otitis media, certain cPses of 
cellul1t1s, and such, there has been a favorable 
response to sulfanilam.ide. This brings out the point 
that a line must be drawn somewhere showing the degree 
of tissue destruction that is necessary before any 
beneficial response is possible. It also shows that 
the drawing of this line, as with the drawing of simi-
lar lines in medicine, is practically impossible. 
Since the wound infections are here non-specific, the 
non-specificity of our drug is again seenl 
The attributes of local implantation are highly 
feasible. Study of effects for guidance of use are 
inadequate. Since a wound is easily seen for study, 
it is not believed ostentatious to think that this 
pharmacologic study is necessary. Since sulfa.nil-
amide is taken up by the body tissues without e.pparent 
damage to them, is it possible that here is a satis-
factory antiseptic? The action is above stated bv 
Jensen, et al to be bacteriocidall 
Clostridi"m welchii infections have also brought 
considerable comment in the last year. Early in the 
history of sulfanilamide, Bohlman (105) reported 
three cases of gas gangrene which responded wonder-
fully to sulfanilamide administration within 24 hours. 
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This finding was apparently confirmed by Kennedy (106). 
Sadusk and Manahon (107) report two cases of 
poatabortal Clostridium welchii infection with positive 
blood cultures in which the blood stream was rapidly 
sterilized by the use of sulfanilamide and the patients 
recovered. They also carried out some experiments and 
adequately showed the bacteriostatic action of sulf-
anilamide on Clostridium welchii in vitro. Such action, 
th9y showed, was inversely proportional to thA number 
of organisms used as th~ 1noculum. 
1Ne are taught that patients who succumb to gas 
gangrene in the first week are overcome with the great 
toxicity of the organism. fiowever, it is seen that in 
the second week the fatalities are from septicemia 
arising from secondar;r infection. Whether the Clos-
tridium welchii, which is seldom the etiologic factor, 
per ~ of the septicemia, is in the blood streem or 
some other organism, it is undoubtedly e. most ideal 
occasion for use of the drug, for more each day it is 
shown that sulfe.nilamide takes care of a multiplicity 
of septicemias. What could be more id,3al for admin-
istration of the drug than a generalized infection 
too acute for tissue destruction, no matter what the 
etiologic factor, within certain limitsl 
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In reviewing th(3 therapeutic effects of sulfanil-
amide as just related, the inadequacy of th9trsat1se 
is seen. New developments are constantly appearing. 
Those now coming t 1) the foreground seem to be dominant-
ly of treatment of different infections than hereto-
fore attacked. Staphylococcus infect ions, bacillus 
infections, subacute-bacterial-endocarditls, and even 
the tubercle bacillus ar~ now being approached. In 
its entirity we are again reminded of the extreme non-
specificity of the sulfonamide compounds and of their 
confusing action. The manner in which these therapeu-
tic effects hook up with cellular metabolism and cat-
abol1am in the body and the metabolism of the bact-
erial invader, must not be forgotten in this mad 
scrambls for blinrJ cure, lest physiology suffer in the 
wake. 
TOXIC 4:FF?.CTS 
Any one who gives sulfanilamide should be acquainted 
with the toxic effects of the drug and the severity to 
which each individual toxic reaction can extend. For 
this reason these effects will be classified accord-
ing to severity. This method of classificetion has 
been used by many writers for reason of its practical-
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nass (36,108). Generally these effects are put in two 
groups, one group of those which are common and seldom 
severe enough to cause alarm; and another of those 
which are rare but dangerous and contraindicate con-
tinuance of treatment. This is a fine way of think-
ing of these reactions, however, th~ grouping is still 
more adequate if a third group is inserted. The 
composite picture might result in the following outline: 
SYMPTOMS OF MILD TOXICITY (Jt,requently se3n, but usually 
do not require discontinuance of the drug.) 
Moderate cyanosis. 
Anorexia, nausea. 
Dizziness, headaches, tinnitus, slight mental confusion. 
Weakness, fatigue. 
SYMPTOMS OF MODRRATE TOXICIT~! (Call for close observa-
tion, but do not call for the discontinuation of 
the drug when it is very much needed.) 
Vomiting, sense of oppression. 
Cyanosis or mild dyspnea. 
Mild, slowly developing anemia. 
Dierrhea and abdominal pain. 
Yild rash or itching. 
Paresthesia, diplopia. 
Acidosis. 
Slight fever. 
SYMPTOMS OF SEVRR~ TOXICI7Y (Call for the immediate 
discontinuation of the drug and corrective measures.) 
Drug fever. 
Tachycardia. 
Leukopenia. 
Jaundice. 
Acute anemia. 
Dermatitis. 
Psychosis, or disorientation. 
Albuminuria, hematuria. 
D1plopia. 
This outline will not always be a true guide to 
severity of a toxic reaction. People who have taken 
the drug may often sey that the nausea with the ad-
ministration can be of an intolerable nature. 
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Patients taking the sulfonamide compounds should 
undouotedl;r be in bed during the course of treatment, 
not take other medicine unless absolutely necess8ry, 
ano should probably not enter any high altitude unless 
required (?). 
Cyanosis is so often seen in the course of therapy 
that it is generally disregarded. It is an erroneous 
belief that it should be present before therapeutic 
effect can be foundJ Long and Bliss ( 13) state, 
"In our experience, cyanosis has not been an alarming 
toxic manifestation and cen genArally be disregarded. 
We have noted its appearance following the administra-
tion of n.o of a gram of sulfanilamide, and, on th" 
other hand, we heve seen patients who were receiving 
large doses of the drug in whom cyanosis was minimal." 
Ey large dos2s it '.•1ould be assumed that Long and .2liss 
meant large doses, for they have done superior work 
with the drugs from all angles and insist upon high 
blood levels l They go on to de scr1.be the "black" or 
"brown" color that either arterial or venous blood 
assumes. When this blood is shaken or bubbled with 
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oxygen it does not regain its normal color. When 
sulfanilemide therepy is stopped, however, the darkness 
disappears and the normal color of the blood is assumed. 
The only writers who agree on the origin of the 
cyanosis are those who attribute it to about three 
factors. ( 109, 110) These men state ths.t both sulf-
hemoglobinemia and rnethemoglobinemia result as well as 
the formation of an unknown pigment. They both agree 
thet the methemoglob1nem1a is dominant. Some workers 
have attributed the cyanosis to th·~ formation of 
sulfhemoglobin predominantly (24, 110-113), some 
attribute it more to formation of methemoglobin (110, 
111,11•-117), and some attribute it to an unknown cause, 
possibly by a discoloration or the red blood cells by 
a pigment formed in the course of sulfanllamide therapy 
(115) or to reduced hemoglobin (118). 
Chesley (117) concludes af'ter his study that he 
had successfully ruled out the formation of sulfhem-
oglobin and methemoglobin in eight cases showing ex-
treme cyanosis. Bigler and Werner {119) conclude that 
the "cause is still not clear. -- -- -- Only in some 
instances has spectroscopic examination of the blood 
revealed presence or sulfhi3moglob1n and methemoglobin 
bands. -- -- -- Also the cyanosis does not seem to 
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depend on oxygen saturation of the arterial blood." 
These men also agree with Long and Bliss (13) in that 
the cyanosis does not seem to depend on the age of the 
pRtient, deily dosage or the length of ti:rie th~ drug 
is administered. 
Colebrook and Kenny (24) attributed a great deal 
of the cyanosis to concurrent use of magnesium sulfate 
as a cethertic during prontosil adm1n1stretion and 
advised its immed1ate sessation. They did not :recommend 
cutting down on sulfur-containing foods or drugs, but 
did encourage diets that would produce a minimum of 
hydrogen sulfide in the lower powel. 
Archer and Discombe (120) believe thst the cyano-
sis is a. sign of approaching danger end insist the.t 
regular blood examinations should be ma.de of all who 
are cye.notic. It will be shown below, however, that 
this should be done in all tr~sted patients. 
The use of methylene-blue in combatjng the cysnosis 
was originally suggested by Hauschild (cited by 121), 
advocated by Wendell, and favored by Hartmann, et al 
( 122). Camp be 11 and Morgan conclude ( 121): " ( 3) In 
methaemoglobinaemia, whether produced by 2 p-aminoben-
zenesulphonemideopyridine or by sodium nitrite, meth-
ylene-blue is effective in causing the rapid disappear-
ance of the cyanosis by converting methaemoglobin to 
hemoglobin. 
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" ( 4) ThA dye is active when given intravenously, 
intramuscularly or by mouth. 
n(5) It is suggested that routine employment of 
methylene-blue in conditions calling for the prolonged 
administration of sulfapyridine may be a useful measure 
preventing cyanosis. 
11 (6) Methylene-blue has no effect in preventing or 
modifying cyanosia of sulphaemoglobinaamia." 
Treatment of the cyanosis truly would rest the 
patient from possible anoxemia. Although methylene-
blue seems good its scope in prevention and treatment 
is limited. The various abnormalities of the blood 
pigment produced by sulfonamides is not fully under-
stood. One to two mg per kg of body wt IV or one to 
two gr (65-130 mg) per os, given every four hours is 
quick to bring and maintain response from rnethemoglo-
binemia. 
Cyanosis deserved special early treatm~nt, for it 
is the stands.rd upon which so many toxic manifestations 
of the administration of the drug E:.re based. Many of 
these unfavorable reactions may· be correctly parallel-
ed to the color of the patient, so to speak, but many 
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of th:;se findings indicate possible further severity 
along similar lines. .As in cases of congenital ano-
malies, w'h3re one is !-re sent alwsvs baivare of another. 
A mild dermatitis ms~r be indication of approaching 
jaundice or agranulocytosis for often these manifes-
tations ere multiple. In the same fashion one who has 
had mild toxic rP-action during one course of therapy 
may be the victim of a more severe episode during a 
ls.ter course. 
A good example of this multiplicity of similar 
reactions is se~n in the nervous system. Those who 
frequently administer the drug are familiar with the 
nausea., dizziness, headaches, tinnitus, and even slight 
mental confusion that frequently accompany early days 
of therapy. Some, on the othAr hand, offer reports 
of rather severe cases of toxic peripheral neuritis 
(123,124). It is of note that these reports deal es-
pecially with some of the newer deriv&tives. Perhaps 
this effect :ls more peculie.r to one of these newer 
compounds than it is of the more established drugs. 
Mild mental disturbances sre not uncommon in p&tients 
who are receiving sulfanilamide. Many individuals 
complain of feeling depressed, although occe_sionally 
the drug causes elation. Frequently, the ability to 
concentrate upon a given problem is disturbed. 
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Frank disorientation is uncommon, although mild confu-
sion is often seen. Hallucinations, both auditory e.nd 
visual, he.ve been noted. Mania is rare but occasion-
ally occurs. Hogan and McNamara (125) have described 
a toxic psychosis which developed in a patient during 
treatment with th~ drug. Following tbA removal of the 
drug the patient showed a steady improvement. Danziger 
( 126) observed e. patient who twice had a toxic res.ction, 
characterized by cyanosis, confusion, and negativism, 
which occurred in each tnstance four days after sulf-
anilamide therapy had be~n stopped. The mechanism of 
this reaction was considered to be unknown. It is 
obvious that in certain instances it is very difficult 
to distinguish between the abnormal m~ntal reactions 
frequently noted in the course of sever(:; acute febrile 
inf'ections, and those due to sulfanilamide therapy. 
Early in the history of the drug several specific 
cases of neuritis were observed. A rather severe toxic 
optic neuritis was reported in 1937 (127). 
Recently two ceses of encephalomyelitis following 
the administration of sul.fanilamide were descril;ed, 
one of which ended fe.tally { 129). The total doses taken 
were small ( 14 gm anrl 18 gm) and if the drug was re-
sponsi (;le the patients must have been more than or-
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dinarily susceptible to it. Vascular changes were seen 
in some of these cases of enoephalomyelitis and their 
relation to the demyelinating lesions was discussed. 
These men offered evidence that patients suffering from 
certain illnesses, including acute rheumatic fever and 
lupus erythematosus, are especially liable to develop 
toxic manifestations aftentaking sulfanilemide. 
Tachycardia is sometimes observed, and not in-
frequently only apparent because of the obvious cyanosis 
which is so often present. Also the tachycardia may 
be blamed upon the changes in the blood stream by meth-
emoglobin and sulfhemoglobin formation. Dazzi (128) 
presents a case which might establish the likelihood 
of cardiac damage resulting from the use of sulfanil-
amide. In this case there was a transient nodal 
rhythm following use of the drug. 
Long and Bliss (130), and Dees and Colston (131) 
offer undisputable evidence that a febrile reaction 
frequently occurs during administration of sulfanil-
amide. Since these works many more reports of a febrile 
reaction have been offered (32,133). These men all 
impress the reader with the contusion that may arise in 
diagnosis when this foreign fever occurs. Hageman and 
Blake (132) noted the freauent occurrence of a fever 
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reaction along with a toxic dermatitis. Gallagher 
(133) analyzes the fevers which he observed and con-
cluded that this reaction was probably based on id-
iosyncracy similar to that seen by other observers in 
other toxic manifestations of the drug therapy. 
An interesting case of severe drug-fever was re-
cently presented in the literature (133). The patient 
underwent a 12-day course of sulfanilam1de therapy in 
1937. During this course the patient developed a 
morbiliform rash and general malaise. In 1939 there 
was again reason to administer an e•tensive regieme 
with the drug. The patient was to have four 20 gr 
doses on the first day. After the second dose general 
malaise, headache, cyanosis, chilliness and fever were 
evident. The drug was stopped immediately, but the 
temperature of the patient continued to rise. Fluids 
were forced. On the second day, although the drug 
was no longer admlnistered, a rash became prominent. 
It was of a morbilliform nature as it had been in the 
previous course. The temperature reached 104 degrees 
by the end of the second day, and the white blood 
count dropped from 17,000 to 9,000 in this short 
interval. on the fourth day the patient was again 
comfortable and afebrile. The rash gradually faded. 
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Long and Bliss (13, page 2'75) state, "')ur ex-
perience with this toxic manifestation (fever) of 
sulfanilamide therapy has been essentially that of 
Hageman anc'l Blake. ~.,e have noted drug fever occurring 
as early as two hours andas late as twenty-one days 
after the institution of sulfan1lsmide, although the 
usual time of appearance of drug fever is between the 
fifth and tenth days of treatment. In our experience 
9 per cent of adults and 3 per cent of children develop 
drug fever in the course of sulfanilamide therapy. 
We have also noted that fever may be the initial sign 
when a serious toxic manifestation such as hepatitis, 
acute hemolytic anemia, or agranulocytosis is develop-
ing. Because of such observations we have come to the 
conclusion that fever constitutes onB of the most 
important warning signs in the course of sulfanil-
amide therapy, and feel that the physician must "atop, 
look, and 11 s ten'' when drug fever develops. " 
Foreign writers (13} have done much in the study 
of the effects of sulfanilamide on spermatogenesis. 
There seems to be no conclusive evidence th.at it is in 
any way damaged. 
The dermatitis that has been so frequently re-
ported as e toxic manifestation of sulfanilamide ad-
ministration, is peculiar. ~arly in the use of the 
drug it wbs noted that patients exposed to sunlight 
were especially affected. Since the great majority 
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ot patients who were ambulatory and most frequently 
exposed to sunlight were those suffering from gon-
orrhea, it was at first thought that there ws.s some 
connection between this disease end the drug adminis-
tration. However, this has been discredited. The 
literature on this phase of toxic effects is voluminous 
(134-142). The rash has been described as exfoliative 
(139), purpuric (141), morbilliform (134), varioliform 
(135), and urticarial (136). Some workers have noted 
a peculiar stomatitis eoncomittent with the exanthem 
(136,138). They described these oral lAsions as being 
similar to mucous patches of secondary syphilis. This 
would be good to remember in diagnostic examination. 
Schwentker and Gelman (144) first described the 
rash. They stated, "It is distinctly morbilliform in 
character, made up of maculopapular lesions slightly 
raised from the surrounding unaffected skin and brownish-
red in colour; although it does not fade completely 
when pressure is applied, the blanching of the rash is 
considerably more marked than that seen with a typical 
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measles eruption. TJsually almost the entire surfe.ce 
of the body is affected, but in some cases the rash 
has been limited to the buttocks or the legs. In some 
of our patients the eruption was seen on the palms of 
the hands and the soles of the feet while the mucous 
membranes were apparently unaffected. There was no 
itching or other abnormal sensation et the site of 
the lesion. 
"The rash usually develops rapidly without any 
prodromal symptoms, the entire evolution occupying 
only about 12 hours. Fever, and general malaise have 
always been present and have sometimes preceded the 
eruption by several hours. The temperature rises sud-
denly, usually ranging between 101 end 103 F., and 
then drops to normal gradually over a period of 2 to 4 
days. The malaise disappears with the fever. No other 
symptoms have been observed. The blood count shows 
no significant alteration. 
"With discontinuance of sulfan1lamide therapy 
the eruption fa.des rapidly and :ma.y disappear completely. 
If the sulfanilamide treatment is not discontinued the 
time of appearance of the primary rash, the eruption 
fades and disappears completely in abm1t seventy-two 
hours." 
67 
Schlesinger and Mitchell (134) offer a good summary 
of dermatitis which we are here concerned with. They 
also described many cases, among which were ten in 
children. They state that the eruption usually is 
first seen in five to seventeen days after original 
administration with continuation. In their series it 
was generally preceded by a leukopenia. An interesting 
"natural history" of the eruption was given: First 
a prodromal period was noted with a fever and transient 
leukopenia, enrl following this the rash appeared, often 
with splenomegaly. A few days after the drug was 
stopped the rash started to gradually fade in most 
every incident. Schonberg (141) points out the manner 
in which the rash can easily be confused with that of 
scarlet fever. 
An interesting case of delayed photosensitization 
has been recently presented (140). In this ~aper it 
is stated that photosensitization of the skin due to 
sulfanilamide is a relatively rare occurrence, but 
should be carefully guarded against because of the 
increased use of the drug. The case reported is 
unusual because it illustrates delayed photosensitivity 
of the skin brought on many months ar'ter therapy was 
started and discontinued, due to exposure to sunlight 
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and artificial sunlight. These photosensitized areas 
were large deep, dark brown patches, apparently fixed 
in the skin, with a sharp line of demarcation, occurr-
ing after withdrawal of the aulfanilamide. Some of 
these areas broke down and caused troublesome ulcers. 
It was emphasized that patients taking sulfanilamide 
should be strictly warned against expostmg themselves 
to sunlight or artificial sunlight during or after the 
taking of sulfanilamide. 
From this multiplicity of manifestations in the 
skin, it is seen that no definite dermatitis can be 
watched for. If one does occur, however, one should 
be certain of its origin, and should watch for other 
toxic reactions. 11Then confronted with such reactions 
the drug should be discontinued only if it is not an 
essential part of the therapeutic regi~me, but if con-
tinued, daily blood counts should be made and other 
key-signs watched forJ 
With the use of aulfapyridine increasing every 
day, and our satisfactory understanding of the pre-
cipitation of a cetyl-sulfap;rridine in the kidney ( 145), 
an oportunity for dramatic action is occasionally 
offered the alert urologist. This is beautifully 
exemplified by Carroll, et al (146). These men had a 
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case of complete anuria following the administration of 
sulfapyridine and, wisely, they did a cystoscopy, 
lavaged the ureters with warm water, and the patient 
rapidly recovered. The first of their conclusions well 
summarize the story and i ta le saons: ''1. The super-
saturation of acetylsulfapyridine crystals during the 
administration of sulfapyridine is sufficient at times 
to cause a complete obstruction in the urinary tract. 
11 2. This condition can be promptly and satisfac-
torily relieved by cystoscopically inserting catheters 
in the ureters and~elves, and lavage with warm phys-
iologic solution of sodium chloride or sterile water. 
"3. These crystals, even in large amounts, which 
cause obstruction, are not opaque to the x-rays; there-
fore a flat roentgenogram is of no value. Thf~ symptoms 
of kidney colic and/or hematuria should make one sus-
picious of crystalline concretions in the urinary 
tract and should not be mistaken for gastric upsets. 
"4. The hematuria noted clinically is probably 
the result of minute traumatism of the mucous membranes 
by the crystals rather than damage to the renal par-
enchyma and therefore is of no grave consequence. 
115. The forcing of fluids in conjunction with 
sulfapyridine therapy is probably appropriate, since 
it will relieve the supersaturation of the urine to 
som9 extent." 
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To be sure, the inert salt of sulfanilamide is 
also precipitated in the urinary tract if the con-
centration is great enough, however, this is unlikely 
since the inert form is not nearly so dominant in the 
blood stream or in the urinary tract as it is with 
sulfapyridine {14?). 
Much experimenting has been done with porphyrin-
uria in rats, both with sulfanilamide and with related 
compounds (148,149). Oakley, and Bensley and Wilen 
have well emphasized the dangers in administration of 
the drug in the face of renal damage (150,151). 
Bensley and ~vilen showed the gravity in delayed sulf-
an1lam1de excretion in a case of pneumonia with renal 
failure. Ravel and Curtis (152) emphasize the serious-
ness of hematuria and abdominal pain associated with 
sulfapyridine administration. Many other workers have 
been concerned with the formation of urinary calculi 
here (153,154). 
Concern will n0xt be directed to the apparently 
most grave toxic manifestations of sulfanilamide, namely 
acute hemolytic anemia, agranulocytic angina and 
hepatitis. The fatalities accredited to the drug are 
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practically always in this category except for a stray 
case of anuria or such now and then. 
Harvey and Janeway (62) offer the first report of 
acute hemolytic anemias, characterized by a sudden 
onset with a marked drop in hemoglobin and red cells, 
jaundice, disturbed liver function, urobilinuria, or 
in severe cases, hemoglobinemia and hemoglobinuria, 
marked reticulocytosis, and leukocytosis. They described 
three cases, all showing these similarities. In each 
incidence the extreme anemia seemed to develop in less 
than 48 hours. Later in th&same quarter Kohn (155) 
gave similar evidence. Since that time there have been 
numerous similar reports (156-158). Wood (158) re-
ported 21 cases of acute anemia which developed in 
patients who had received sulfanilamide in the johns 
hopkins Hospital. He noted an incidence of acute anemia 
of 8.3 per cent in 144 children and 2.4 per cent in 
378 adults. No predisposing factors were noted in the 
analysis that Wood made of these patients, but he did 
find that all of the patients who developed acute anemia 
had fever at some time during the period of sulfanilamide 
therapy. No relationship to dosage, concentration of 
the drug in the blood, or acidosis was observed. In 
all of the 21 cases the fall in hemoglobin was shown to 
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begin between twenty-four and seventy-two hours after 
treatment was started. The time of maximum anemia 
occurred between the third and seventh days, with the 
greatest number of patients (nine} develo~:ing maximum 
anemia on the fifth day. Nausea and dizziness were 
found to be the earliest symptoms of an approaching 
anemia, while fever and an increased urobilinuria were 
the earliest signs of the toxic reaction. One or 
more transfusions were needed to combat the anemia in 
13 of the 21 reported cases. None of the patients 
died. Free hemoglobin was demonstrated in the serum 
of at least one of Wood's patients. Four of the 21 
patients were subsequently given sulfanilamide for 
therapeutic purposes and three of them developed acute 
hemolytic anemia. The patients were subsenuently 
gliven sulfanilamide for therapeutic purposes and three 
of them developed acute hemolytic anemia. The patient 
who escaped anemia did not have fever at the time of 
the second course of the drug. 
Several workers have found that there is an 
increased reticulocyte count accompanied by a moderate 
decrease in the hemoglobin and red blood cells in 
patients who were being treated with sulfanilamide 
( 159 ,160). 
Long and Bliss state (13), "Our own experience 
leads us to believe that sulfanilamide produces a mild 
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hemolytic anemia in many individuals. This is es-
pecially true if traatment with the drug is prolonged 
over a period of several weeks. These anemias are 
characterized by a slow, but progressive, drop in the 
hemoglobin and red blood cells, a moderate reticulocy-
tosis, and often a mild urob111nuria. Anemia of this 
type is not to be feared and does not constitute a 
contraindication to further therapy. If the hemoglobin 
drops below 60 per cent and further treatment with the 
drug is n(;eded, a transfusion is indicated. However, 
if at this point the drug can be stopped without fear 
of a recurrence of the infection, the blood rapidly 
regenerates." 
Agranulocytosis in its apparently limited varia-
tions is undoubtedly the most serious of the toxic 
manifestations. A very pathetic picture is painted 
by the literature of this quite sudden death, suffering 
with severe angina in most instances. Thia manifes-
tation has been attributed to Prontosil, Neoprontosil, 
sulfanilamide, benzyl sulfanilamide, sul:t'e.nilyl di-
methyl sulre.nilamide, and sul:t'apyridine (161-177). 
The general effects of sulfanilamide upon the 
white blood cells in general have been studied at great 
length. Bigler et al (119) attempted to show that there 
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was generally a marked depression of the number of white 
cells. In some instances, these men state, the depres-
s:!on hinges upon being a leukopenie.. However, they 
found the lower lirrits of their vi1hi te blood counts 
to be a.bout 5,000 per cubic millimeter, and they 
admitted that part of the decrease was apparent since 
the white cells were not fewer in comparison to other 
cellular blood elements. Campbell (159) did not find 
any effect of sulfanilamide upon the white blood cells. 
Hedicl extensive studying on the subject, which is not 
yet closed by any means. 
Agranulocytosis has been known to occur in in-
toxication with various other drugs. Dinitrophenol, 
amidopyrine, allonal, and novaldin have been known to 
produce a similar picture, although the severity seldom 
approaches that of the reported cases with sul.fan1le.m1de 
intoxication (162). No correlation between these drugs 
has been seen. 
Jennings andSouthwell-Sander (160) present a very 
interesting case in which there was both agranulocyto-
sis and a pro.found anemia. J)olgopol and Hobart ( l '75) 
suggest that blood counts only be done twice a week. 
They point out that in most of the fatalities reported, 
no blood count was done in the interval of development 
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and that if such was watched twice a week regularly, 
the development would no doubt be seen. Most men, 
however, agree with Borst (165), in his early article, 
where he emphasizes that to avoid these fatalities 
daily blood counts and observation of thro&t is necessary. 
Not only granulocytopenia but also hyperleucocytosis 
has been attributed to sulfanilemide and allied 
compounds (177). 
Borst (165) reported one of the earliest cases of 
fatal outcome. He attributed this death to th~ ad-
ministration of not more than 1.8 gm of prontosil daily, 
although the patient's previous history may have indi-
cated some predisposing disease of the bone marrow. 
This investigator decided, in view of the number of 
severe toxic reactions concomitant with his use of 
prontosil, to treat subsequent patients with sulfanil-
amide. Since that time, the number of severe toxic 
reactions concomitant with the use of other derivatives 
of sulfanilamide and sulfanile_mide itself have been 
quite well balanced. 
Young (1?8) reported another of the early cases of 
agranulocytosis with fatal termination. His was in a 
case of acute rheumatism which, following the failure 
of salicylate therapy, had been treated with 3 gm of 
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sulfanilamide daily for 18 days. Treatment was dis-
continued at this time because the clinical condition 
of the patient was frankly worse. A blood specimen 
taken f'our days later showed complete agranulocytosis 
and positive culture for hemolytic Staphylococcus aureus 
and Streptococcus viridans, although a negative blood 
culture had been reported three weeks earlier. Death 
occurred on the following day. On~ the day prior to 
death the blood showed 1,880 lymphocytes and no leu-
kocytes. The author believed the agranulocytosis to 
be either of the-idiopathic t:vpe of unknown etiology 
or to be due to sulfan1lam1de therapy. Other cases, 
reported in the opening paragraph of discussion of this 
toxic effect, are quite similar to these two. The 
dosage varies within certain limits, being quite small 
in some cases. The onset of the depression of the 
white cells is also not always spaced the sam0 from 
the day of onset of therapy, but in genr-iral, the de-
pression starts in from two to five days. Young's 
case, above described, is an exception in that it 
apµerently took over two weeks for the agranulocytosis 
to develop. 
Reletions to bone marrow disease and-sept icemil! 
as above shown in two cases, brings up the question 
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of whether or not to use sulfenilemide and its deriva-
tives in the control of sepsis with secondary agranulo-
cytosis or in sepsis followin~· granulocytopenia that 
is induced by other drugs such as before m~ntioned. 
Again Long End Bliss ( 13) may be turned to for supremA 
opinion. They state, "1ie think that in patients suf-
fering .from egre.nulocytosis and streptococcal sepsis, 
therapy with these drugs is not only indicated, but may 
be life-saving." They also advise, for other cases of 
agranulocytosi s from sulf'anilamide, "The first step to 
be taken when egrenulocytosis develops is to provide 
for the rapid elimination of the drug. Fluids should 
be forced vigorously by the peroral and, if necessary, 
by the intra.venous route. The diet is unimportant, 
except that it should have a high v&tamin content, 
espeoially of vitamin C. This may be reinforced by 
the daily intravenous injection of 500 milligrams of 
cevitamic acid. If angina is a prominent symptom, the 
throat should be treated by the topical application 
of sodium perborate or neoarsphenamine, there being 
no indication that the use of either of these drugs is 
dangerous in this condition. 1He are inclined to think 
that the less a patient suffering from agrs.nulocytosis 
is disturbed by misguided attempts at palliation, the 
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better. There is scant evidence that nucleotide 
preparations are of value in this condition and we 
never advise their use. Transfusions also should be 
avoided unless the hemoglobin drops below 60 per cent, 
since transfused blood is of questionable therapeutic 
value in the absence o:f a definite hemoglobin det'icit.n 
Hageman andBlake (130) and Long and Bliss (L~2) 
were early to report jaundice as one of the toxic man-
ife ste. tions of sulfanilamide therapy. 'I'he'j'de scribed 
this as !)eing o:f a mild nature and did not e.ttach much 
significance to it, except that it represented some 
sort o:f liver damege, the extent of which was not 
understood. Long and Elisa associated this jaundice 
with marked decrease in liver function in some instances. 
They also noted that therA ws.a no acute hemolytic anemia 
in the patients observed, for as before stated a jaun-
dice is folmd in those cases quite often. Other 
workers were quick to verify these reports (49, lry9-
182). These men also reported cases of extreme hep-
atitis with fatalities. 
The ce.se presented by Cline {181) is diff'erent 
from the others in t:hat 1 t was an acute yellow atrophy 
in the course of sulfanile.mide therapy. The patient 
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had been given the drug over a period of two months, 
and at the termtnation of theperiod it was found that 
he had been taking it far in excess of th&physician's 
orders. The cese gave many diagnostic troubles. It 
waa at first thought to be a catarrhal jaundice. There 
was no rash present as found in some other reported 
cases. The illness from the drug covered a period of 
ten days and ended fatally. The signs of liver insuf-
ficiency gradually progressed during this period. An 
autopsy was done, and the typical findings of acute 
yellow atrophy were recorded. 
Bann1ck and his associates (179) have reported two 
instances of fatal jaundice in the course of sulf·-
anilamide therapy. They, however, attributed only one 
of the deaths directly to the drug. Saphirstein (180) 
described an e.xfolie.ting dermatitis and acute hepatitis 
in a patient who received aulfanilamide over a period 
of seventeen days. The dermatitis and hepatitis 
cleared within two weeks. Garvin (182) has observed 
five patients who developed a toxic hepatitis in the 
course of, or subsequent to, sulfanilamide therapy. 
In four of these, the hepatitis was considered definite-
ly to be a toxic reaction to the drug. Two of the 
patients developed jaundice and hepatitis while receiv-
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ing the drug. In the other three sulfanilamide had 
been stopped four, seven and thirty-five days before 
evidence of liver injury became apparent. An exfoliat-
ing dermatitis was associated with the hepatitis in 
three patients, one of whom died. There was no reason 
to suspect the existence of previous liver damage in 
any of these patients. One patient had previously 
suffered from a toxic reaction to sulfanile.mide. Other 
reports have been published of fatal toxic hepatitis 
from drug ad.ministration (183,184). 
Charles P. Baker, M.A., M. D., o:f the University 
of Nebraska College of Medicine, offers the following 
case for analysis. The patient was admitted to the 
Methodist hospital, Omaha, Nebraska, on August 16, 1939. 
History: Caesarian section for full term baby 2-20-39. 
past 15 years "colitis" which consisted of gas pains end 
belching. This we.a relieved during the pregnancy. 
Two weeks ago joint pains with s vollen tfoints. Patient 
treated with sulfanilamide. Following this noted 
nausea, dizziness, faintness and confusion. Four 
days ago first noted yellow tinge to skin. Has had no 
abd:cminal pain but says upper abdomen has been tender. 
Following the jaundice joint pains have been relieved. 
Physical examination: Skin markedly yellow. Tenderness 
in right upper quadrant. 
Laboratory: Hemoglobin 84~, 'J'IBC s,ooo. Urine-- bile 
present. Stools very light with bile present in small 
amounts occasionally. Van den Bergh immediate direct 
reaction. Serum bilirubin 18 mg~. 
Course: 8-21-- Hb ?5~, RBC 3,?50,000. Stools slight 
81 
test for bile. Serum bilirubin 15 mg~. ~dema present. 
Given transfusions. 
8-23-- roentgen studies. No calculi found. Liver not 
enlarged. 
9-14-- serum bilirubin 31 mg%. Considerable ascites 
found. Total serum protein 4.5 mg%. 
9-20-- serum bilirubin 15 mg1,. 
9-27-- paracentesis. 
9-30-- serum bilirubin 14 mg%. 
10-2-- irrational. 
10-3-- dd. 
An autopsy permit was obtained. The liver was 
found to weigh only 750 gm. The ducts were entirely 
open. The organ was firm, and nodular in appearance. 
In microscopic section some post mortem change was noted 
in the liver. The connective tissue was greatly in-
creased in amount, in some regions being the only tissue 
present except for compressed bile ducts. Most all 
of the paranchymal tissue was more or less completely 
degenerate. ~owever, in one area there was fine evidence 
of attempted regeneration. Here the cords of cells 
were fresh in appearance, arxl they were arranged in 
irregular formation about central veins which were not 
well centered. No other significant finding was 
apparent. 
In considering this case it is noted that the 
toxicity hed overwhelmed the restorative powers of the 
liver. No doubt the liver of one person is different 
in its regenerative powers than that of another. The 
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great predominance of degeneration over regeneration in 
this specimen shows the failure of this restorative 
power here. Sections of the bile ducts were taken at 
many levels to be assured th8t no obstruction had been 
present. Previous liver damage :Ts not in evidence in 
the story. The fact that the patient had had previous 
toxic reaction to sulfanilamide showed the apparent 
idiosyncracy to the drug which here seemed to be 
present. 
The edema of this patient was no doubt due to two 
great f'actors: Through the intir::ate relationship of 
the liver with the protein metabolism of the body the 
protein level of the blood was considerably reduced as 
shown by the periodic laboratory studies. With the 
great contraction of the liver which was evident at 
autopsy it is easy to understand that considerable 
portal obstruction must have been present. 
No other drugs are known to have been administered 
to the patient in this case, and apparently only the 
usual dosage was taken over a period of about ten days. 
The difficulty in diagnosis here emphasizes the 
fact that many of these cases could easily go unreported. 
The intimate hook up with protein metabolism is here 
again suggested by the liver reaction in the nature of 
an idiosyncre.cy. 
SUMMARY 
In the statement of purpose of this paper it was 
said that an attempt would be made to find som~thing 
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in connnon with the effects of sulfanilamide and all1ed 
compounds, as interpreted from the literature on the 
subject. It is felt that an important generality can 
now be, not made, but only e~phasized. This generality 
concerns not only the therapeutic erfects, but also 
the toxic manifestations of drug administration as well. 
This gross impression is seen in most all of the late 
11 terature, e.nd can :~asily be round between the lines 
of the earliest. This one ract-- that in deciding 
where to use the drug, why, and when, what to watch for 
in the giving, how to watch for it, why, and when, 
and if it comes, in many more relatives-- it is not the 
micro-organism that is concerned, the concomitant 
morbidity that may be present or the fear of reaction 
that is to control and guide therapy-- it ls the manner 
in which these m1cro-organisms manifest themselves in 
the body, the ability of the body to standany mild ther-
apeutic measures, and the response to those measures 
as interpreted by a fair knowledge of what to expect. 
During the affair with Massengill and Company, 
before mentioned, a layman, or even many students of 
medical science, might have said, ''That is sad-- so 
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many people meeting death because of this new drug, 
but it is e wonderful discovery. 1Ne must give the men 
credit for that." Few even realize that the early 
history of the drug was not even American! In th~ same 
misinterpretation, that has followed the developm~nt of 
our collective knowledge of the drug, it is noted that 
the first report of therapeutic action of the compound 
was es acting against a staphylococcus infection in 
man (septicemia). Still, this was not heeded because 
the first proof of therapeutic activity was in ex-
periments with streptococci-- experiments that, in-
cidently, don't work in the laboratory with the staph-
ylococcus. However, the professional world wes quick 
to assume that the drug was e specific for streptococci. 
It is only now coming to light thet F multiplicitv of 
micl'o-organisms are affected. Staphylococcus septicemias 
can be treated quite as well as streptococcus ones if 
they are sttacked at a similar stage in the disease 
process where ther~ is parallel tissue destruction. 
In the same wav, through the few years of active 
history of the sulfonamide compounds, we turn from the 
remarkable work of one man to that of another, for-
getting to retain that of the first. The literature 
has been too profuse and voluminous for gen·'lral study, 
but soon each practicing person will have read at 
least one of the frequently appearing short summaries 
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that are now seen, and a mora representative impression 
will be almost universal. 
Dangers are seen in the mistaken impression that 
the drug is more or less a specific for streptococci. 
General use in sore throats is seen to be harmful as 
before shown, and at the same time an important op-
portunity to save a life may be missed by harboring 
this belief. These opportunities may arise in the face 
of concomitant morbidity which may have to tJe bucked, 
but a thourough understanding of what is being bucked 
to affect must be realized. 
Intimacy with a recent case of toxic hepatitis 
has been interesting in this report. The analysis of 
the morbid process involves many physiological considera-
tions as before shown. If signs of hepatic insuffic-
iency are met, the administration of the drug should 
be stopped at once and palliative measures resorted to. 
These signs appear early enough to be adequate danger 
signals if daily vigilance is possible. 
Physicians in general practice and in most of the 
special practices of medicine and surgery have no 
choice about using these drugs. Some have hesitated 
because of the occasional toxic reactions. Others 
have been overly zealous without due regard for them. 
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The extreme value of these drugs demands that the 
physician use them; the possibility of toxic reactions 
demands that he use them intelligently. 
The precautionary measures needed in using these 
drugs are not difficult. So much laboratory work may 
be found an inconvenience but these drugs are often 
life-saving measures and deserve the full attention 
of the attending physician. 
CONCLTJSIONS 
1. It is not the micro-organism so much as the 
manner in which that micro-organism manifests itself 
in the morbid process in the body, that is concerned 
with in determining the therapeutic effects of sulf-
onamide compounds. 
2. The toxic effects of sulfonamide compounds 
need not be feared if daily vigil is kept during ad-
ministration. 
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